anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method of a nano-drug and application of the nano-drug in osteosarcoma treatment. The Cys-8E material synthesized by the method has good biocompatibility and strong drug encapsulating capacity. The nano-carrier is used for encapsulating Apatinib and GSK-J4 to prepare nano-drug (NP)  J4+Apa  ) Then can target the tumor part of osteosarcoma, and has better drug delivery capacity for osteosarcoma stem cells which cannot be acted by traditional drugs. The nano-drug NP  J4+Apa  Can induce the apoptosis of osteosarcoma stem cells and remarkably improve the treatment effect of Apatinib and GSK-J4. At the same time, the nano-drug NP  J4+Apa  Apatinib and GSK-J4 can be prevented from acting on normal cells, and toxic and side effects can be reduced. The nano-drug NP of the invention  J4+Apa  Has the advantages of targeting osteosarcoma stem cells, small side effect and the like, and has good application prospect and wide development space in the clinical field of osteosarcoma.
The involvement of serine esterase activity in a number of clinical conditions is disclosed. A rapid test for serine esterase activity is disclosed, this test involving (a) fixing the sample which is to be tested, e.g. in formalin; and (b) contacting the fixed sample with a solution containing N-alpha benzyloxy carbonyl-L-lysine thiobenzyl ester and a chromogen (e.g. Fast Blue BB). The use of this test as a diagnostic indicator or monitor of the progress of therapeutic treatment is disclosed. Techniques for the treatment of diseases, particularly auto-immune diseases, are also suggested.
Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
beta-glucuronidase (beta-G) activity can be inhibited by glucoronic acid (GA) and/or glucoronic acid gamma-lactone (GAL), opt. in combination with vitamin B12. Compsns. contain e.g. 0.1-20 (pref. 0.1-10 or 0.1-5) wt. % GA or GAL and B12 concn. is 1-1100 gamma per ml soln. emulsion or suspension or per g semi(solid)prepn. GA and GAL can be used to protect animal or plant tissue against microorganisms esp. against bacteria and fungi. beta-Cr increases the resistance of bacterial to bacteridical and bacteriostatic medicaments, the damaged microorganisms are reactivated and stimulated to fresh growth. GA and GAL decrease the beta-G concn. and intensify the antibiotic therapy and are esp. suitable for treatment of acne, boils, cystopyolitis, cholesystitis, sinusitis, otitis, resistance to antibiotics, foudroyant septicaemia in babies, prophylactic treatment of inflamed mucous membranes, influenza, topical treatment of wounds, pathological loss of hair, increased dandruff formation, and greasiness, and skin itches. GA and GAL also reduce the smell due to sweat and increase the strength of the gums, making parodontosal development difficult. GA and GAL make tissues more resistant to Mycobacterium tuberculosis and allergene and the cancer-like proliferation on the roots of plants, caused by Bacterium tumefaciens. Vitamin B12 potentiates the inhibitor activity of GA and GAL.
With the increasing number of young breast cancer (BC) patients worldwide, concerns about hair loss and skin change persist among BC survivors. This study aimed to evaluate the hair loss and skin changes in Asian BC patients and to compare them according to the treatment regimens. This study enrolled 322 patients scheduled to undergo BC surgery. Hair loss and skin changes were assessed at the following two time points: one day before surgery and 6 months after surgery. Patients who had received systemic anticancer treatment before surgery were assigned to the neoadjuvant treatment group, while patients who were scheduled to receive systemic anticancer treatment were assigned to the adjuvant treatment group. In the adjuvant treatment group, patients with taxane-based chemotherapy had significantly higher odds of increased hair loss, a higher melanin index, and an increased volume of wrinkles (p < 0.0001, p = 0.0110, and p = 0.0371, respectively). In the neoadjuvant treatment group, hair loss was reversed in most patients at 6 months after surgery. Clinicians should inform BC patients about the potential for hair loss and skin changes and provide supportive care to mitigate the effects on the patients' quality of life.
Patients taking gabapentin should not drive until they have gained sufficient experience to assess whether gabapentin impairs their ability to drive. Driving performance studies conducted with a prodrug of gabapentin (gabapentin enacarbil tablet, extended-release) indicate that gabapentin may cause significant driving impairment. Prescribers and patients should be aware that patients’ ability to assess their own driving competence, as well as their ability to assess the degree of somnolence caused by gabapentin, can be imperfect. The duration of driving impairment after starting therapy with gabapentin is unknown. Whether the impairment is related to somnolence [see Warnings and Precautions (5.4 )] or other effects of gabapentin is unknown.   
Moreover, because gabapentin causes somnolence and dizziness [see Warnings and Precautions (5.4)], patients should be advised not to operate complex machinery until they have gained sufficient experience on gabapentin to assess whether gabapentin impairs their ability to perform such tasks.
Despite evidence for the effectiveness of policies that target obesogenic environments, their adoption remains deficient. Using methods and concepts from complexity and political science (Stock-and-Flow analysis and Punctuated Equilibrium Theory) and a qualitative literature review, we developed system maps to identify feedback loops that hinder policymaking on mitigating obesogenic environments and feedback loops that could trigger and sustain policy change. We found numerous self-reinforcing feedback loops that buttress the assumption that obesity is an individual problem, strengthening the biomedical and commercial weight-loss sectors' claim to "ownership" over solutions. That is, improvements in therapies for individuals with obesity reinforces policymakers' reluctance to target obesogenic environments. Random events that focus attention on obesity (e.g., celebrities dismissing soda) could disrupt this cycle, when actors from outside the medical and weight-loss sector (e.g., anti-weight stigma activists) successfully reframe obesity as a societal problem, which requires robust and politically relevant engagement with affected communities prior to such events taking place. Sustained prioritization of policies targeting obesogenic environments requires shared problem ownership of affected communities and nonhealth government sectors, by emphasizing cobenefits of policies that target obesogenic environments (e.g., ultraprocessed food taxation for raising revenue) and solutions that are meaningful for affected communities.
Prior to treatment, ensure appropriate personnel and medication are available to treat reactions (e.g., hypersensitivity, other reactions) that occur during infusion and shortly after infusion. Prior to infusion with Infliximab, patients may be premedicated with histamine-1 receptor antagonists, histamine-2 receptor antagonists, acetaminophen, and/or corticosteroids [see Warnings and Precautions (5.7)].

For mild to moderate reactions during the infusion, consider slowing or stopping the infusion. Upon resolution of these reactions, may reinitiate at a lower infusion rate and/or with histamine-1 receptor antagonists, histamine-2 receptor antagonists, acetaminophen, and/or corticosteroids. Discontinue the infusion if the mild to moderate reactions reoccur.

Discontinue the infusion if severe hypersensitivity reactions occur during the infusion.
The patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
PURPOSE:To provide an antiphlogistic and analgesic ointment having excellent transcutaneous absorptivity and antiphlogistic and analgesic activities, and having no side effects inherent to the oral administration, by using ketoprofen as an active component in combination with an emulsion base composed of higher alcohol, hydrocarbons, water, and emulsifying agent. CONSTITUTION:The objective antiphlogistic and analgesic ointment contains 0.5-5wt% ketoprofen of formula, 5-15wt% higher alcohol (e.g. stearyl alcohol), 10-20wt% hydrocarbons (e.g. white petrolatum, 51.5-82.4wt% water, 1-3wt% emulsifying agent (e.g. polyoxyethylene alkyl ether), and 0.1-0.5wt% preservative (e.g. p-oxybenzoic acid ester). Ketoprofen is known as a drug for oral administration, and its side effects such as gastroenteric, hepatic and renal disorders caused by the continuous oral administuration can be prevented by using  the compound as external agent. The above ointment may be incorporated with  absorption acclerating agent, moisture retaining agent, etc., and is preservable  for a long period.
The invention discloses a pure Chinese herbal preparation for treating lithiasis and belongs to the scope of pure traditional Chinese medicines, and the preparation is used for treating various lithiasis. The pure Chinese herbal preparation is prepared from the following medicines in compatibility: 15g of lygodium japonicum, 15g of umbellate pore fungus, 20g of pseudo-ginseng, 20g of plantain herb, 15g of raspberry, 20g of fructustribuli, 30g of endothelium corneum gigeriae galli, 40g of corn stigma, 40g of walnuts, 15g of caulis akebiae, and the balance of oyster and honey. A proper amount of water is added to the pure Chinese herbal preparation; and the pure Chinese herbal preparation is prepared into water-honeyed pills or capsules, or the pure Chinese herbal preparation has an original taste, is powder-shaped and is decocted for taking. According to the medicines in compatibility, the pure Chinese herbal preparation can be used for clearing heat, promoting diuresis, promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation and removing the lithiasis and accumulation so as to fulfill the aim of eliminating the various lithiasis by supplementing nutrition, adjusting endocrine and improving the human immunity. Patients with the lithiasis with the size of not more than 6mm*5mm need to continuously take the pure Chinese herbal preparation for one course of treatment; patients with the lithiasis with the size ranging from 6mm*5mm to 10mm*85mm need to continuously take the pure Chinese herbal preparation for three courses of treatment; and patients with the lithiasis with the size being more than 10mm*85mm need to continuously and correspondingly take the pure Chinese herbal preparation for more courses of treatment according to the courses of treatment of the patients with the small lithiasis. The pure Chinese herbal preparation is taken with warm water for three times per day, and one course of treatment lasts for 15 days.
Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
BACKGROUND: Posterior spinal fusion (PSF) and hip reconstruction are commonly indicated surgeries in children with cerebral palsy (CP), particularly those functioning at GMFCS levels IV and V. These are large and often painful procedures, and previous literature suggests that hip surgery is more painful than spine surgery in this patient population. The purpose of this study is to investigate pain scores and opioid use following hip and spine surgery in a large cohort of children with CP, including many patients who have undergone both types of surgery.
METHODS: A retrospective chart review was performed to identify children with CP who underwent hip reconstruction and/or PSF at a tertiary children's hospital between 2004 and 2022. Charts were reviewed for demographic data, pain scores, pain medication usage, duration of hospital stay, and complications.
RESULTS: Data were collected for 200 patients (101 male, 99 female) who met inclusion criteria. Eighty-seven patients underwent hip reconstruction, 62 spinal fusion, and 51 both hip and spine surgery asynchronously. Median (interquartile range) age at the time of surgery was significantly older for spinal fusion compared with hip surgery [13.1 (4.9) vs. 8.1 (5.7) y, P <0.0001]. Length of stay was significantly longer after PSF, with a median of 6 (4) days compared with 2 (1) days after hip surgery ( P <0.0001). Both maximum and average daily pain scores were similar following hip and spine surgery, with the exception that average pain scores for hip surgery were slightly higher on postoperative day 1, hip=1.73 vs. spine=1.0 ( P <0.0001). The amount of opioids used, expressed as morphine milligram equivalents (MME)/kg were similar in the hip and spine surgery groups; however, it was significantly lower in the hip surgery group on postoperative day 0, hip=0.06 versus spine=0.17 ( P <0.0001). For the 51 patients who underwent both hip and spine surgery, the amount of opioids used mirrored that for the entire group (similar MME/kg, though only statistically significantly less on POD 0 and 3), and pain scores were not significantly different between the 2 groups except in 2 circumstances. The 2 exceptions in these 51 patients both demonstrated lower pain scores in patients after hip surgery, including lower maximum pain scores on POD 1 ( P =0.041), and lower average pain scores on POD3 ( P =0.043).
CONCLUSIONS: This is the largest series to date comparing postoperative pain in children with CP after hip and spine surgery, including 51 of 200 patients who underwent both types of surgery. The results of this study demonstrate that hip surgery is not more painful than spine surgery in children with CP, and conflict with the traditional belief that hip surgery is more painful. This is important information for health care providers when counseling patients and families regarding these surgeries in children with CP.
LEVEL OF EVIDENCE: Level 3.
An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game...Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
Patients (n=211) who accepted neoadjuvant systemic therapy followed surgery were from Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University and No. 900 Hospital of The Joint Logistic Support Force from April 1, 2012, to May 30, 2022.
The invention relates to a Chinese medicinal composition for relaxing bowel. The composition is prepared from the following raw materials in part by weight: 10 to 25 parts of desertliving cistanche, 10 to 20 parts of radish seed, 10 to 20 parts of cassia seed and 10 to 25 parts of bighead atractylodes rhizome. The composition has the advantages of strict prescription, remarkable special effect, wide resource of raw materials and low cost. Because the prescription is simple, the quality control of the medicament is simple. The composition is prepared into the soft capsule formulation according to the characteristics of active ingredients and has accurate dosing; the contents can be very quickly absorbed by a human body in the form of liquid state after the capsules are disintegrated in vivo; and the soft capsules have the advantages of smooth surfaces, good mouthfeel and easy swallowing. The clinical primary pharmaceutical effect verifies that the composition has the advantages of definite therapeutic effect, rapid response, no toxic or side effect, safety, effectiveness, safe carrying and convenient eating for middle aged and elderly constipation patients. Clinical experiments verify that the effectiveness ratio reaches 100 percent and the composition has bright application prospect and market prospect.
Phospholipase D1 (PLD1) contributes to cancer development and progression through its effects on cell proliferation, survival, invasion, metastasis, angiogenesis, drug resistance, and modulation of the tumor microenvironment. Its central role in these processes makes it a promising target for novel cancer treatments aimed at inhibiting its activity and disrupting the signaling pathways it regulates. In this study, we aimed to investigate the effect of PLD1 inhibition on gastric cancer cell growth using a novel peptide inhibitor, TAT-TVTSP. PLD1, which plays a role in cancer progression, catalyzes the conversion of phosphatidylcholine into choline and phosphatidic acid through hydrolysis. To effectively target PLD1 in cells, we engineered TAT-TVTSP by fusing a PLD1-inhibitory peptide (TVTSP) with a cell-penetrating peptide (TAT). We observed that TAT-TVTSP effectively inhibited PLD1 activity in AGS gastric cancer cells. Moreover, TAT-TVTSP significantly inhibited the mammalian target of the rapamycin signaling pathway, including the phosphorylation of key downstream targets such as S6K1, AKT, S473, glycogen synthase kinase-3b, and forkhead box O1. TAT-TVTSP did not induce cell death, but it triggered cell cycle arrest by activating p21 and p27 via AKT phosphorylation. Functional assays revealed that TAT-TVTSP significantly impaired the colony-forming ability of AGS cells, thus inhibiting cell proliferation. Transwell and wound-healing assays revealed that this peptide disrupted the cellular behaviors critical to cancer progression, such as migration and invasion. In vivo, TAT-TVTSP significantly reduced tumor growth in the xenograft model of gastric cancer without any toxicity. Overall, our results suggest that TAT-TVTSP is a novel therapeutic agent for PLD1-mediated cancers.
Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
AIMS: RNA-binding proteins (RBPs) play pivotal roles in carcinogenesis and immunotherapy. Leucine-rich pentapeptide repeat-containing protein (LRPPRC) is crucial for RNA polyadenylation, transport, and stability. Although recent studies have suggested LRPPRC's potential role in tumor progression, its significance in tumor prognosis, diagnosis, and immunology remains unclear.
MAIN METHODS: We comprehensively analyzed LRPPRC expression in tumors using various databases, including Human Transcriptome Cell Atlas (HTCA), University of California Santa Cruz (UCSC), Human Protein Atlas (HPA), Sangerbox, TISIDB, GeneMANIA, GSCALite, and CellMiner. We examined the correlation between LRPPRC expression level and prognosis, immune infiltration, immunotherapy, methylation, biological function, and drug sensitivity. Single-cell analysis was performed using Tumor Immune Single Cell Hub (TISCH) and CancerSEA software. Patients with acute myeloid leukemia (AML) were categorized based on LRPPRC levels for functional and immune infiltration analyses. The role of LRPPRC in cancer was validated using in vitro experiments.
KEY FINDINGS: Our findings revealed that LRPPRC was highly expressed in almost all cancer types, indicating its significant prognostic and diagnostic potential. Notably, LRPPRC was associated with diverse immune features, such as immune cell infiltration, immune checkpoint genes, tumor mutational burden, and microsatellite instability, suggesting its value in guiding immunotherapy strategies. Within AML, the high-expression group had lower levels of immune cells, including CD8+ T cells. In vitro experiments confirmed the inhibitory effects of LRPPRC knockdown on AML cell proliferation.
SIGNIFICANCE: This study highlights LRPPRC as a reliable pan-cancer prognostic and immune biomarker, particularly in AML. It lays the groundwork for future research on LRPPRC-targeted cancer therapies.
PROBLEM TO BE SOLVED: To provide an aerosol composition for forming foams, capable of forming the good foams in spite of having a high content of a lower aliphatic alcohol in a stock solution, having a good use touch, and forming the foams having high shape retainability. SOLUTION: This aerosol composition for forming foams comprises 45.0-75.0 wt.% of a lower aliphatic alcohol, 0.01-3.0 wt.% of lecithin, 0.1-3.0 wt.% of a nonionic surfactant, and a propellant. The aerosol composition preferably further contains 0.01-3.0 wt.% of a thickening agent, especially preferably at least one of carboxyvinyl polymers, xanthan gum and cellulose derivatives. The propellant preferably comprises a liquidized petroleum gas, and is used in an amount of 2-10 pts.wt. per 100 pts.wt. of a stock liquid.
The aim of this research was to estimate the immunopotentiation effect of brown algae Padina boergesenii water extract on Nile tilapia, Oreochromis niloticus through resistance to Pseudomonas putida infection. Gas Chromatography Mass Spectrometry was utilized to characterize the seaweed phytoconstituents. One hundred and twenty-six fish were divided in triplicates into two equal groups corresponding to two diet variants that used to feed Nile tilapia for 20 successive days: a basal (control), and P. boergesenii water extract supplemented group. Fish samples were collected at 10-days intervals throughout the experiment. Serum biochemical constituents, total antioxidant capacity (TAC), and some immune related genes expression of the spleen and intestinal tissues of experimental fish were studied, as well as histological examination of fish immune tissues. Moreover, following 20 days of feeding, the susceptibility of Nile tilapia to P. putida infection was evaluated to assess the protective effect of the used extract. The findings indicated that the studied parameters were significantly increased, and the best immune response profiles were observed in fish fed P. boergesenii water extract for 20 successive days. A bacterial challenge experiment using P. putida resulted in higher survival within the supplemented fish group than the control. Thus, the lowered post-challenge mortality of the fish may be related to the protection provided by the stimulation of the innate immune system, reduced oxidative stress by higher activity of TAC, and elevated levels of expression of iterleukin-1beta (IL-1β), beta-defensin (β-defensin), and natural killer-lysin (NKl). Moreover, the constituents of the extract used showed potential protective activity for histological features of the supplemented fish group when compared to the control. Collectively, this study presents a great insight on the protective role of P. boergesenii water extract as an additive in Nile tilapia feed which suggests its potential for improving the immune response against P. putida infection.